Xenon Pharmaceuticals Inc. Profile Avatar - Palmy Investing

Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is …
Biotechnology
CA, Burnaby [HQ]

Cash Flow Statements

13 Sheets · Starting from 2023
In Million USD. Margins, Growth Rates In %
Metric 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Operating Activities
Operating Cash Flow (OCF)
-13.00 45.00 -3.00 - - -18.00 -19.00 -28.00 -34.00 -4.00 -48.00 -69.00 -98.00 -145.00
Operating Cash (Net)
-13.00 45.00 -3.00 - - -18.00 -19.00 -28.00 -34.00 -4.00 -48.00 -69.00 -98.00 -145.00
Accounts Receivable
-11.00 11.00 - - - - - - - - - - - - - - -1.00 - - 1.00 - -
Accounts Payable
- - - - - - - - - - - - - - - - 4.00 2.00 2.00 8.00 3.00
Working Capital
- - - - - - - - - - - - - - - - - - - - - - - - - -
Investing Activities
Used Cash (Net)
13.00 - - -11.00 -3.00 10.00 -47.00 24.00 -28.00 -66.00 -16.00 -246.00 -296.00 -117.00
Capital Expenditure
- - - - - - -1.00 - - - - - - - - -1.00 -2.00 -2.00 -2.00 -5.00
Purchases of Investments
- - - - -17.00 -15.00 - - -47.00 -28.00 -77.00 -140.00 -228.00 -389.00 -551.00 -793.00
Sale/Maturity of Investment
14.00 1.00 6.00 13.00 10.00 - - 52.00 48.00 75.00 214.00 144.00 258.00 682.00
Property, Plant, Equipment (P&PE)
- - - - - - -1.00 - - - - - - - - -1.00 -2.00 -2.00 -2.00 -5.00
Acquisitions (Net)
- - - - - - -13.00 - - - - -52.00 -48.00 -75.00 -214.00 -144.00 296.00 -682.00
Other Investing Activities
- - - - - - 13.00 10.00 -47.00 52.00 48.00 75.00 214.00 144.00 -296.00 682.00
Financing Activities
Used Cash (Net)
- - - - -4.00 -41.00 - - -23.00 -7.00 -111.00 -27.00 -85.00 -447.00 -278.00 -353.00
Debt Repayment
- - - - -1.00 - - - - - - -6.00 -8.00 - - -16.00 - - - - - -
Dividends Paid
- - - - - - - - - - - - - - - - - - - - - - - - - -
Common Stock
- - - - - - - - - - - - - - - - - - - - - - - - - -
Other Financing Activities
- - - - -4.00 -1.00 - - 23.00 6.00 8.00 - - - - - - 278.00 353.00
Cash Balances
Begin of Period
14.00 13.00 60.00 37.00 72.00 58.00 17.00 20.00 67.00 24.00 45.00 175.00 57.00
End of Period
13.00 60.00 37.00 72.00 58.00 17.00 20.00 67.00 24.00 45.00 175.00 57.00 148.00
Change
- - 46.00 -22.00 34.00 -13.00 -41.00 3.00 47.00 -42.00 20.00 130.00 -118.00 91.00
Non-Cash Balances
Depreciation and Amortization
1.00 - - - - - - 1.00 - - - - - - - - - - - - 1.00 3.00
Stock Based Compensation
- - - - - - - - 3.00 2.00 2.00 - - 2.00 5.00 10.00 20.00 32.00
Other
- - - - - - - - - - - - - - -4.00 - - - - 1.00 5.00 -4.00
Highlighted metrics
Free Cash Flow (FCF)
-13.00 45.00 -3.00 -1.00 -18.00 -19.00 -29.00 -35.00 -5.00 -50.00 -71.00 -101.00 -150.00
Cash Conversion Cycle (CCC)
- - -30.00 -17.00 -31.00 -178.00 -438.00 496.00 - - 20.00 -14.00 22.00 5.00 - -
Invested Capital
- - - - - - - - - - - - - - - - - - - - - - - - - -
Other Operating Inflows/Outflows
End of XENE's Analysis
CIK: 1582313 CUSIP: 98420N105 ISIN: CA98420N1050 LEI: - UEI: -
Secondary Listings
XENE has no secondary listings inside our databases.